Click on the plus icon to show bio.
Peter Sommerness, President and CEO
Pete joined Respicardia® as CEO in January of 2018. Prior to Respicardia, Pete was a Partner in the healthcare practice of McKinsey & Company, a global strategy consulting firm. Pete has nearly 20 years of experience in the medical device space, including over 12 years of operating experience at Guidant Corporation and Boston Scientific – across cardiac rhythm management (CRM) and cardiac electrophysiology (EP). Pete held leadership roles in field sales, market development, upstream marketing and portfolio, and most recently led the expansion of Boston Scientific’s Cardiac Electrophysiology business as VP and General Manager. Pete holds B.A., B.E. and M.E. degrees in Engineering from Dartmouth College and an M.B.A. in Finance with high honors from the Booth School of Business at the University of Chicago.
Robin Germany, M.D.: Chief Medical Officer
Dr. Robin Germany joined Respicardia®, Inc. in 2008, coming from the University of Oklahoma where she was the Director of Heart Failure Treatment and Medical Director of the Heart, Lung and Vascular Clinic for 5 years. She followed her training in cardiovascular diseases at the University of Oklahoma with additional training in heart failure and electrophysiology. Her research focused on utilizing implantable devices to improve the care of heart failure patients. While serving as Chief Medical Officer for Respicardia®, Dr. Germany retains her title of Clinical Assistant Professor at the University of Oklahoma.
Tim Hauch: Chief Financial Officer
Tim came to Respicardia®, Inc. in 2010. He leads financial and business development operations at Respicardia®, bringing his industry expertise from his role as Vice President of Business Development with start-up super Dimension, along with seventeen years at Medtronic. His prior roles included responsibilities for identifying key growth markets and defining acquisition targets, as well as leading cross-functional teams through acquisition, investment, license, divestiture and development transactions. Tim’s breadth of experience encompasses both public and private M&A transactions as well as both sides of strategic investments. He received a B.A. from the University of Wisconsin-Oshkosh and earned an M.B.A. from the University of Chicago Booth School of Business. Tim also passed the CPA exam.
Todd Goblish: Vice President of Research and Development
Todd Goblish joined Respicardia®, Inc. in February 2008. His extensive medical device experience in implantables, neurostimulation and respiration prepared him well to lead the research, development and operations of the remedē® System. Todd’s prior experience includes five years as VP of R&D at Pulmonetic Systems whose product successes led to their acquisition by Viasys Healthcare, followed by Cardinal Health. Prior to Pulmonetic Systems, Todd held various engineering management positions over nine years with the Cardiac Rhythm Management and Neurological Divisions of Medtronic. He holds a B.S. in Electrical Engineering from Marquette University and an M.S. in Computer Engineering from National Technological University.
Linda Nelson: Vice President Clinical Affairs
Linda joined Respicardia®, Inc. in 2014 bringing over 15 years of medical device experience. Prior to Respicardia®, Linda was the Director of Clinical in AF Solutions at Medtronic where she participated in the acquisition of CryoCath and Ablation Frontiers, leading the clinical group through PMA submissions that resulted in approval of the Cryoballoon for paroxysmal AF. Linda has held various leadership and research roles in heart failure, heart transplant, electrophysiology, and atrial fibrillation. Linda received a B.S.N. from St. Olaf College in Northfield, MN and an M.B.A. from the University of St. Thomas.